Table 1.
Demographic, clinical, and pathological characteristics of patients with non-metastatic colon cancer.
| Variable (N) | N | % |
|---|---|---|
| Total number of patients | 69 | 100 |
| Median age (range) at recruitment, years (69) | 61 (19–87) | |
| Gender, no. males/no. females (69) | 36/33 | 52.2/47.8 |
| Histological grade (67) | ||
| Mucinous adenocarcinoma | 5 | 7.5 |
| Well-differentiated adenocarcinoma | 4 | 6 |
| Moderately-differentiated adenocarcinoma | 57 | 85 |
| Poorly-differentiated adenocarcinoma | 1 | 1.5 |
| Primary tumor site (69) | ||
| Proximal colon | 23 | 33.3 |
| Distal colon | 46 | 66.7 |
| KRAS mutation status (54) | ||
| Wild-type | 35 | 64.8 |
| Mutant | 19 | 35.2 |
| NRAS mutation status (54) | ||
| Wild-type | 49 | 90.7 |
| Mutant | 5 | 9.3 |
| BRAF mutation status (47) | ||
| Wild-type | 47 | 100 |
| Mutant | 0 | 0 |
| MMR status (64) | ||
| Proficient | 57 | 89.1 |
| Deficient | 7 | 10.9 |
| Tumor size (69) | ||
| 1 | 4 | 5.8 |
| 2 | 20 | 29 |
| 3 | 37 | 53.6 |
| 4a/4b | 8 | 11.6 |
| Lymph node status (69) | ||
| N0 | 33 | 47.8 |
| N+ | 36 | 52.2 |
| pS (69) | ||
| I | 18 | 26.1 |
| IIA/IIB | 15 | 21.7 |
| IIIA/IIIB/IIIC | 36 | 52.2 |
| Therapeutic strategy (69) | ||
| Adjuvant chemotherapy | 40 | 58 |
| Follow-up | 29 | 42 |
| Median CEA at baseline, C1 (available for 65/69) | 2.5 (0.1–158) | |
| Median CEA at follow-up, C2 (available for 37/56) | 1.6 (0.6–33) | |
| Median CTC (8 mL) at baseline, C1 (available for 69/69) | 20 (0–94) | |
| Median CTC (8 mL) at follow-up, C2 (available for 56/56) | 13 (0–69) | |
| CTM at baseline, C1 (available for 69/69) | ||
| Presence | 13 | 18.8 |
| Absence | 56 | 81.2 |
| CTM at follow-up, C2 (available for 56/56) | ||
| Presence | 8 | 14.3 |
| Absence | 48 | 85.7 |
| Tumor-node-metastasis staging according to 2017 UICC guidelines. | ||